ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives $8.00 Consensus Price Target from Brokerages

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) have earned an average rating of "Buy" from the eight analysts that are presently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $8.00.

PRQR has been the subject of a number of research reports. Evercore ISI restated an "outperform" rating on shares of ProQR Therapeutics in a report on Friday, July 11th. JMP Securities restated a "market outperform" rating and set a $8.00 target price on shares of ProQR Therapeutics in a report on Friday, June 27th. Cantor Fitzgerald restated an "overweight" rating and set a $8.00 target price on shares of ProQR Therapeutics in a report on Friday, June 27th. Finally, Oppenheimer reduced their target price on shares of ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th.

Institutional Investors Weigh In On ProQR Therapeutics

Several hedge funds have recently made changes to their positions in PRQR. Adage Capital Partners GP L.L.C. lifted its position in shares of ProQR Therapeutics by 164.9% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 9,602,280 shares of the biopharmaceutical company's stock valued at $25,446,000 after acquiring an additional 5,976,813 shares in the last quarter. Woodline Partners LP purchased a new stake in ProQR Therapeutics in the 4th quarter worth approximately $9,426,000. Affinity Asset Advisors LLC purchased a new stake in ProQR Therapeutics in the 4th quarter worth approximately $7,486,000. Millennium Management LLC lifted its position in ProQR Therapeutics by 1,864.4% in the 4th quarter. Millennium Management LLC now owns 2,827,280 shares of the biopharmaceutical company's stock worth $7,492,000 after buying an additional 2,683,351 shares in the last quarter. Finally, Aberdeen Group plc purchased a new stake in ProQR Therapeutics in the 1st quarter worth approximately $2,461,000. Hedge funds and other institutional investors own 32.65% of the company's stock.

ProQR Therapeutics Stock Down 0.2%

NASDAQ:PRQR traded down $0.01 during trading hours on Friday, reaching $2.23. 73,092 shares of the company's stock were exchanged, compared to its average volume of 437,346. The company has a market capitalization of $234.09 million, a P/E ratio of -6.36 and a beta of 0.36. ProQR Therapeutics has a 12 month low of $1.07 and a 12 month high of $4.62. The business's 50-day simple moving average is $2.00 and its two-hundred day simple moving average is $1.89.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). The business had revenue of $4.89 million for the quarter, compared to the consensus estimate of $4.90 million. ProQR Therapeutics had a negative return on equity of 53.49% and a negative net margin of 157.04%. As a group, sell-side analysts anticipate that ProQR Therapeutics will post -0.31 earnings per share for the current fiscal year.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).